Tuznue: Withdrawal of the marketing authorisation application



Prestige Biopharma Belgium BVBA withdrew its application for a marketing authorisation of Tuznue for the treatment of certain forms of breast cancer and gastric (stomach) cancer.
The company withdrew the application on 14 September 2022.

  • List item

    Questions and answers on the withdrawal for the marketing authorisation of Tuznue (trastuzumab) (PDF/90.61 KB)

    First published: 14/10/2022
    Last updated: 13/12/2022

  • Key facts

    Product number
    International non-proprietary name (INN) or common name
    • trastuzumab
    Active substance
    • trastuzumab
    Date of withdrawal
    Company making the application
    Prestige Biopharma Belgium
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating